Navigation Links
Tuberculosis Experts Outline Proposals to Speed Up Drug Development

Proposals to accelerate the development of tuberculosis (TB) drugs were outlined today at the conclusion of a two-day symposium titled "No Time to Wait," convened// in New York this week by the international medical humanitarian organization Doctors with the support of Howard P. Milstein and Weill Cornell Medical College's Abby and Howard P. Milstein Program in Chemical Biology.

The symposium brought together more than 100 TB specialists, drug developers and regulators, policy makers, donors and activists to outline practical proposals to fill the gaps in TB drug research and development (R&D).

"We are failing people with TB," said Dr. Tido von Schoen-Angerer, Director of MSF's Campaign for Access to Essential Medicines. "Diagnosing and treating TB is one of the greatest challenges facing health care providers around the world. Things are going from bad to worse with multi-drug resistant TB and even extensively drug resistant (XDR) TB, particularly in settings with high HIV prevalence. The urgency for new tools could not be greater - there is no time to wait."

TB kills nearly two million people per year, primarily because of inadequate diagnostic and treatment tools. While roughly one drug for HIV has been developed each year since the start of the epidemic 25 years ago, the latest novel TB drug in today's standard therapy was developed in the 1960s.

Basic science is not being translated into new TB drugs needed to improve treatment, according to an MSF analysis of the TB drug pipeline. There are not enough promising drugs in the pipeline and serious funding gaps prevent the development of candidate drug compounds through to clinical trials.

Resistance to TB drugs is growing at a rapid pace, with 450,000 new cases of drug-resistant TB detected each year. The recent detection of hundreds of cases of XDR-TB, which is extremely difficult and sometimes impossible to treat, adds further urgency to the situatio n. TB remains the main killer of people with HIV, in large part because existing TB drugs and tests are poorly adapted for use in people with HIV/AIDS.

"In TB research, there needs to be a convergence of innovation, incentive, and access," said Dr. Carl Nathan, Rees Pritchett Professor of Microbiology and Chairman of Microbiology and Immunology at Weill Cornell Medical College. "We need to see openness, leadership and collaboration among all TB actors."

Experts attending the symposium emphasized several actions that urgently need to be taken to improve the situation:

· Drastically increase funding of TB R&D
· Accelerate drug discovery
· Expand clinical trial capacity and speed up clinical development
· Commit to global TB R&D leadership
· Support new approaches to R&D, such as a global R&D framework

"We need increased clinical trial capacity, fast-tracked clinical trials, and criteria for compassionate use of important candidate drugs," said Dr. von Schoen-Angerer. "To make any real difference, we need to see a dramatic increase in funding and political will."

The symposium emphasized a need to build a global TB R&D movement, as was critical to the advancements in HIV drug development. Strong political leadership is required to improve collaboration between scientists, drug developers, care providers, and affected individuals.

Symposium participants agreed on the need for a massive increase in funding by governments for TB R&D, as current TB drug discovery initiatives are insufficient. Participants voiced support for an effort launched by governments at the World Health Assembly in May 2006 to examine alternative ways to prioritize and finance health-needs-driven R&D.



Source: Bio-Bio Technology'"/>




Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Defending against Tuberculosis
3. Easier Tests To Detect Tuberculosis
4. Smoking Increases The Risk Of Developing Tuberculosis Infection
5. Gene Target For Tuberculosis Identified
6. WHO declares Tuberculosis – ‘An Emergency’ in Afrca
7. New Vaccine Targeted At Effective Treatment Against Tuberculosis
8. Time for A.R.Rahman to rock the Tuberculosis Awareness Programme
9. BCG vaccine for both Protection and treatment of Tuberculosis
10. Diagnostic Procedure For Tuberculosis Made Easy
11. PA-824 drug effective against Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: